Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 12/20 | 0.69 |
| ▸ | CA2 | P00918 | 12/20 | 0.69 |
| ▸ | CA9 | Q16790 | 9/20 | 0.69 |
| ▸ | CA4 | P22748 | 7/20 | 0.69 |
| ▸ | CA12 | O43570 | 3/20 | 0.69 |
| ▸ | CA3 | P07451 | 3/20 | 0.69 |
| ▸ | CA6 | P23280 | 3/20 | 0.69 |
| ▸ | CA5A | P35218 | 3/20 | 0.69 |
| ▸ | CA7 | P43166 | 3/20 | 0.69 |
| ▸ | CA13 | Q8N1Q1 | 3/20 | 0.69 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.69 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | CA11 | O75493 | 1/20 | 0.62 |
| ▸ | THRB | P10828 | 1/20 | 0.62 |
| ▸ | BLM | P54132 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.62 |
| ▸ | GLS | O94925 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18656466 | 0.86 | CA1 (0.68) | CA1CA2CA9CA4CA12 | |
| SCHEMBL10797173 | 0.82 | CA1 (1.00) | CA1CA2CA9CA4CA12 | |
| SCHEMBL11930741 | 0.82 | CA1 (0.76) | CA1CA2CA9CA4CA12 | |
| SCHEMBL13660392 | 0.81 | CA1 (0.46) | CA1CA2CA9CA4CA12 | |
| SCHEMBL18100211 | 0.78 | CA1 (0.72) | CA1CA2CA9CA4CA12 | |
| SCHEMBL11929008 | 0.78 | CA1 (0.69) | CA1CA2CA9CA4CA12 | |
| SCHEMBL3501152 | 0.78 | CA1 (0.69) | CA1CA2CA9CA4CA12 | |
| SCHEMBL19687 | 0.77 | CA1 (0.70) | CA1CA2CA9CA4CA12 | |
| Hydrochloric Acid SCHEMBL10464123 | 0.77 | CA1 (0.70) | CA1CA2CA9CA4CA12 | |
| Acetazolamide SCHEMBL23219 | 0.77 | CA1 (1.00) | CA1CA2CA9CA4CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220213047-A1 | CARBONIC ANHYDRASE INHIBITORS FOR TREATMENT OF NEISSERIA GONORRHOEAE INFECTION | PURDUE RESEARCH FOUNDATION (US) | 2022-07-07 | — | — | US | disclosed |
| WO-2020131980-A1 | CARBONIC ANHYDRASE INHIBITORS AND ANTIBIOTICS AGAINST MULTIDRUG RESISTANT BACTERIA | PURDUE RESEARCH FOUNDATION (US) | 2020-06-25 | — | — | WO | disclosed |
| US-20160279084-A1 | TARGETED TREATMENT OF ANEROBIC CANCER | UNIVERSITY HOSPITALS CLEVELAND MEDICAL CENTER | 2016-09-29 | — | — | US | disclosed |
| US-7592366-B2 | Therapeutic compounds | ALLERGAN, INC. (US) | 2009-09-22 | — | — | US | disclosed |
| US-20080015231-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. | 2008-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160279084-A1 | TARGETED TREATMENT OF ANEROBIC CANCER | SLC16A3, SLC16A1, SLC16A7 | CA1 142/4885CA2 7/4885CA9 10/4885 |
| US-20080015231-A1 | THERAPEUTIC COMPOUNDS | GOT2, ANXA5, COXFA4L2 | CA1 3120/4885CA2 2343/4885CA9 1716/4885 |
| US-20220213047-A1 | CARBONIC ANHYDRASE INHIBITORS FOR TREATMENT OF NEISSERIA GONORRHOEAE INFECTION | CA4, CA7, CA9 | CA1 11/4885CA2 6/4885CA9 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.